Clinical Trial Update: Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update indicates cemiplimab is being studied in high-risk or locally advanced luminal and triple-negative breast cancer, with the study currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Breast Cancer

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Invasive Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING